TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07533266: A Multi-center, Randomized, Double-blind, Parallel-group, Active-controlled, Phase IV Clinical Trial to Evaluate the Efficacy and Safety of Fexuclue Tab. in Prevention of NSAIDs-induced Peptic Ulcer

Sponsor: Daewoong Pharmaceutical Co. LTD. · Phase: PHASE4 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 360 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$8,499,200

Rescue Site Savings

+$5,604,160

Unlock Full NCT07533266 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07533266 Rescue Dossier →